Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023.
Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.
Yahoo3 days agoROP
Illumia Names Sean Bruton as Chief Information Security Officer
SCOTTSDALE, Ariz., September 01, 2026--Illumia, a leading provider of technology solutions that power payments, identity, commerce and foodservice operations across higher education, healthcare and corporate campuses, today announced the appointment of Sean Bruton as Chief Information Security Officer (CISO). Bruton brings more than 25 years of experience in cybersecurity and compliance leadership, including experience building compliance technology, leading managed security services, and using
Yahoo3 days agoROP
3 Dividend Stocks with Unbelievable Streaks but Barely Pay Investors
Some dividend stocks boast decades of unbroken raise streaks yet leave income investors with almost nothing to show for it. These three companies sit in that strange category, and the tension between their legendary consistency and their near-invisible payouts reveals something important about what a dividend streak actually means.
Yahoo4 days agoROP
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
Columvi® (glofitamab) will be added to the Singapore Ministry of Health's (MOH) CDL and MAF List. Starting 1 September 2026, this milestone ensures that eligible Singaporeans and Permanent Residents will have subsidised access to the medication in public healthcare institutions.[1]
Yahoo4 days agoROP
Roche Holding (SWX:ROP) Secures FDA Clearance For Alzheimer’s Blood Test
Roche Holding (SWX:ROP) received FDA approval for its Elecsys pTau217 blood test for Alzheimer's disease in the U.S. The Elecsys pTau217 test is designed to identify amyloid pathology using a blood sample, widening access to dementia diagnostics across U.S. labs. The FDA also cleared expanded use of Roche's PATHWAY HER2 and VENTANA HER2 Dual ISH tests in metastatic gastroesophageal cancers. These approvals broaden options for HER2 testing in cancer care and support more tailored treatment...
Yahoo7 days agoROP
CoStar (CSGP) Up 7.7% Since Last Earnings Report: Can It Continue?
CoStar (CSGP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo8 days agoROP
Roper Technologies: A Cautious Buy Despite The Risks
Roper's Q2 8.5% revenue growth and a 233% EPS increase were driven by equity gains from Indicor and robust segment performance. Read why ROP stock is a Buy.
SeekingAlpha12 days agoROP
Tracking Akre Capital Management Portfolio - Q2 2026 Update
Akre Capital's Q2 2026 13F portfolio fell to ~$5.12B, with 19 positions and significant concentration in MA, MCO, BN, KKR, and FICO. Read more on the portfolio here.
SeekingAlpha12 days agoROP
Is Roche Holding (SWX:ROP) Fully Valued After Its Latest US Manufacturing Push?
Genentech’s plan to invest $750 million in a new device fill finish facility in Hillsboro, Oregon, has put Roche Holding (SWX:ROP) back in focus for investors watching its U.S. manufacturing footprint. See our latest analysis for Roche Holding. Roche Holding’s recent manufacturing announcements have landed against a strong run in the stock, with a 13.0% 1 month share price return and a 15.4% year to date share price return, while the 1 year total shareholder return of 48.0% points to building...
Yahoo13 days agoROP
Roche (SWX:ROP) Stock Could Be Below Fair Value After US Manufacturing Expansion
Roche Holding stock has delivered a 58.5% return over the past three years, yet the current valuation checks give a more mixed read on how much upside may be left in the price. Roche Holding's 58.5% three year return highlights that shareholders have already seen solid gains, so fresh buyers need to think carefully about what is now priced in. Large ongoing investments in U.S. manufacturing facilities and collaborations in diagnostics can support expectations for future cash flows, while the...
Yahoo14 days agoROP
What Are Wall Street Analysts' Target Price for Roper Technologies Stock?
Roper Technologies has underperformed the market, while analysts remain moderately optimistic on its future prospects.
Yahoo15 days agoROP
Roper Technologies' $3.2 Billion Bet On Itself Looks Smart
Roper repurchased over 8% of its shares for $3.2B during a software sector selloff, capitalizing on depressed valuations. Read more on ROP stock here.
SeekingAlpha15 days agoROP
Illumia Adds PayPal and Venmo for College Tuition Payments
SCOTTSDALE, Ariz., August 19, 2026--Illumia, an award-winning leader in innovative higher education, healthcare, senior living, and corporate technology, today announced that participating colleges and universities can now accept tuition and fee payments using PayPal or Venmo through their existing payment portals.
Yahoo16 days agoROP
Roper's Illumia Adds PayPal, Venmo As Payment Platforms
Illumia, an award-winning leader in innovative higher education, healthcare, senior living, and corporate technology, today announced that participating colleges and universities can now accept tuition and fee payments
Benzinga16 days agoROP
RBC Capital Reiterates Sector Perform on Roper Technologies, Maintains $417 Price Target
RBC Capital analyst Deane Dray reiterates Roper Technologies (NASDAQ:ROP) with a Sector Perform and maintains $417 price target.
Benzinga17 days agoROP
Roper Technologies (NASDAQ:ROP) Flashes Bull Flag Breakout Setup Amid Strong Technical Trend
ROPER TECHNOLOGIES (ROP) shows a strong technical setup with a 7/10 rating and bull flag pattern, offering a defined breakout entry above $408.09.
ChartMill18 days agoROP
Roche (SWX:ROG) Stock Fair Value Edges Higher As Analysts Weigh Pipeline Growth
Roche Holding now sits on a refreshed fair value estimate of CHF 370.31, up from CHF 359.22. This gives you an updated reference point for where analysts see the stock’s long term potential. This move lines up with recent research that highlights contrasting views on the company’s pipeline, from optimism around giredestrant and 2027 catalysts to more cautious takes on how much upside is already captured in forecasts. Read on to see how these shifting assumptions shape the evolving narrative...
Yahoo24 days agoROP
DAT: Contract van and reefer rates make record June-to-July gains
PORTLAND, Ore., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Contract rates for dry van and refrigerated truckload freight posted their largest June-to-July increases on record, according to DAT Freight & Analytics, provider of the industry’s leading load boards and freight analytics. The average contract linehaul rate, which excludes a fuel surcharge, increased 13 cents per mile for van freight and 9 cents per mile for refrigerated (“reefer”) freight. Rates climbed even as freight volumes declined across
Yahoo24 days agoROP
Roper Technologies, Inc. (ROP) Presents at Oppenheimer 29th Annual Technology, Internet & Communications Conference Transcript
Roper Technologies, Inc. (ROP) Oppenheimer 29th Annual Technology, Internet & Communications Conference August 11, 2026 9:55 AM EDTCompany...
SeekingAlpha24 days agoROP
Software rebound is real but selective, Jefferies says, as power crunch reshapes AI buildout
Software stocks are staging a comeback in the second half of the year, according to Jefferies analysts, who pointed to strong results from ServiceNow Inc (NYSE:NOW, XETRA:4S0), SAP, Roper Technologies, Atlassian (NASDAQ:TEAM) and Cloudflare as evidence the sector is shaking off fears of...
Yahoo25 days agoROP
Argus Research Upgrades Roper Technologies to Buy, Announces $450 Price Target
Argus Research analyst John Eade upgrades Roper Technologies (NASDAQ:ROP) from Hold to Buy and announces $450 price target.
Benzinga29 days agoROP
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.
Yahoo29 days agoROP
Roche (SWX:ROP) Starts Breast Cancer Trial With Evexta Bio Using Two Drug Candidates
Roche Holding (SWX:ROP) has entered a clinical collaboration with Evexta Bio to test a combination of rupitasertib and giredestrant. The partnership focuses on a Phase 1b trial in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer. The agreement centers on a breast cancer segment with significant unmet medical need. Roche Holding, traded as SWX:ROP, is adding this collaboration to an oncology portfolio that already plays a central role in the company’s identity. The stock...
Yahoo29 days agoROP
Roper Technologies to present at Oppenheimer Technology Conference
SARASOTA, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that it is presenting at the Oppenheimer 29th Annual Technology, Internet & Communications Conference on Tuesday, August 11, 2026, at 9:55 AM (Eastern Time). A link to the webcast presentation will be available in the “Investors” section of the Company’s website at www.ropertech.com. About Roper Technologies Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Roper has
Yahoolast monthROP